New arsenal against drug-resistant cancers

Combining camptothecin, a well-known anticancer alkaloid, with veliparib, an anticancer agent still under clinical trial, researchers have reported good results in treating drug-defying cancers of the breast, ovary, lungs and colon1.

The combination therapy kills the cancer cells by inhibiting the activity of two key enzymes that orchestrate DNA replication, protein synthesis and DNA repair in the cell’s nucleus.

Scientists from Kolkata-based Indian Association for the Cultivation of Science used the drug combination on cell cultures to find that it selectively killed cancer cells and spared the healthy ones. The scientists say these insights could be useful for devising new chemotherapy using drugs that are undergoing clinical trials for a host of cancers. read more

Leave a Reply